Nkarta (NASDAQ:NKTX) Posts Quarterly Earnings Results

Nkarta (NASDAQ:NKTX) announced its quarterly earnings data on Wednesday. The company reported ($0.35) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.06, Zacks reports.

Nkarta Stock Performance

NKTX traded up $0.60 on Thursday, reaching $1.97. The company had a trading volume of 8,274,968 shares, compared to its average volume of 1,057,777. The company’s fifty day moving average is $2.01 and its 200 day moving average is $2.90. The stock has a market cap of $138.67 million, a P/E ratio of -1.05 and a beta of 0.90. Nkarta has a fifty-two week low of $1.31 and a fifty-two week high of $11.84.

Insider Transactions at Nkarta

In other news, CEO Paul J. Hastings sold 17,378 shares of the stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $2.20, for a total transaction of $38,231.60. Following the transaction, the chief executive officer now owns 319,859 shares in the company, valued at approximately $703,689.80. This trade represents a 5.15 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 8.70% of the company’s stock.

Analyst Ratings Changes

Several analysts have issued reports on the stock. HC Wainwright reaffirmed a “buy” rating and set a $18.00 price target on shares of Nkarta in a research report on Thursday. Stifel Nicolaus cut their target price on shares of Nkarta from $15.00 to $14.00 and set a “buy” rating for the company in a research note on Thursday. Finally, Needham & Company LLC reiterated a “buy” rating and set a $11.00 price target on shares of Nkarta in a report on Thursday. Six research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $14.86.

Nkarta Company Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.